OIS@AAO

Envisia Therapeutics: Overcoming Compliance Issues in Glaucoma

By Jackie Wengrod | November 11, 2016

Compliance with topical medication drops to manage glaucoma “is horrid,” said Benjamin Yerxa, PhD, co-founder and president, Envisia Therapeutics. Poor compliance results in disease progression,…

Read More
mati-therapeutics

Mati: Punctal Plugs for Sustained Delivery

By Jackie Wengrod | November 11, 2016

The Evolute Punctal Plug Delivery System provides sustained ocular drug delivery that “is as good or better than what’s out there,” said Bob Butchofsky, Mati…

Read More

Encore Vision Developing Topical Treatments for Presbyopia

By Jackie Wengrod | November 11, 2016

Encore Vision’s EV06 ophthalmic solution (lipoic acid choline ester 1.5%) is “a prodrug that metabolizes into choline and lipoid acid, two naturally occurring substances,” that…

Read More

Mynosys Cellular Devices Eyes An Ideal Capsulotomy

By Jackie Wengrod | November 11, 2016

Mynosys has developed the means to create “an ideal capsulotomy,” in its ZEPTO device, said John Hendrick, president and chief executive officer. The ZEPTO is…

Read More

Novaliq: Transforming Tears

By Jackie Wengrod | November 11, 2016

Novaliq has been transforming how clinicians think about artificial tears since the company’s inception, said Bernhard Günther, co-founder and chief executive officer. NovaTears/EvoTears is a…

Read More

FluidVision: Designed to Restore True Accommodation

By Jackie Wengrod | November 11, 2016

PowerVision’s fluid-controlled accommodating intraocular lens (IOL) is “the first true shape-changing lens that mimics the eye’s natural accommodative process,” said co-founder, president, and chief executive…

Read More
Trracey Ophthalmics

Tracery Drawing Finer Lines for AMD

By Mario Admin | November 10, 2016

Shelley Boyd, MD, president and CEO of Tracery Ophthalmics Inc., introduced the company’s clinical-stage “functional ophthalmic imaging platform” to OIS@AAO. The company – funded by…

Read More

Allegro’s Luminate Achieves Primary Endpoint in DME Trial

By Mario Admin | November 10, 2016

  Top-line Phase IIb results showed Allegro Ophthalmics’ first-in-class integrin peptide inhibitor, Luminate, achieved its primary and secondary endpoints for efficacy and safety in treatment…

Read More

Alimera Tackles IOP Questions of Iluvien Head On

By Mario Admin | November 9, 2016

“This is not your father’s steroid,” Alimera Sciences’ CEO Dan Myers told the Posterior Segment Company Showcase at OIS@AAO 2016 in discussing new evidence that…

Read More

pSivida: Sustained-Release Therapies

By Mario Admin | November 9, 2016

CHICAGO—pSivida has created a business model to solely concentrate on preventing blindness through proprietary sustained-release drug technologies, said newly appointed president and CEO Nancy Lurker.…

Read More

Aerie Pharmaceuticals Using ROCK Inhibitors to Change Glaucoma Management

By Mario Admin | November 9, 2016

CHICAGO—Aerie’s CEO and chairman, Vincent Anido, Jr., PhD, has said the company’s goal is to become a major ophthalmic pharmaceutical firm by using Rho-kinase inhibitors…

Read More
gavin-herbert

Ophthalmology Pioneer Herbert Recounts Allergan’s Beginnings

By Mario Admin | November 9, 2016

Gavin Herbert, founder, Allergan, took over the company when he was in his mid-20s, and he built an industry leader by hiring the right people…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.